Retatrutide and What's Next: The GLP-1 Pipeline in 2026

Why this matters

Why a Pipeline Update Belongs in Every Weight-Loss Conversation

Today's standard of care — semaglutide and tirzepatide — produces 15–22% mean weight loss. The next wave of agents in late-stage trials reads at 20–25%+ mean weight loss with potentially better tolerability, oral options, and monthly dosing. Several should reach FDA review in 2026–2027.

Patients starting therapy today, particularly with long horizons, deserve to know what's coming. Insurance posture, dose strategy, and class-switching all change once the next wave is on label.

[Verify all trial status, FDA filings, and approval timing at publish — this area is moving monthly.]

Retatrutide

Retatrutide — Triple Agonist (Eli Lilly)

Mechanism: triple agonist of GLP-1, GIP, and glucagon receptors. The glucagon component is the new lever — it appears to increase energy expenditure on top of the appetite-suppression and insulin-sensitization mechanisms of GLP-1/GIP.

Phase 2 data (published in NEJM 2023) reported ~24% mean weight loss at 48 weeks at the highest dose, with weight loss still on a downward trajectory at week 48 rather than plateauing.

Phase 3 TRIUMPH program: enrolling and reading out across obesity, type 2 diabetes, MASH, sleep apnea, and osteoarthritis indications. FDA filing anticipated 2026–2027 pending Phase 3 results.

If Phase 3 reproduces Phase 2 with acceptable safety, retatrutide would set a new ceiling for non-surgical weight loss.

Orforglipron

Orforglipron — Once-Daily Oral Small Molecule (Eli Lilly)

Mechanism: non-peptide small-molecule GLP-1 receptor agonist. Unlike Rybelsus, it is not a peptide and has no SNAC food-timing requirement.

Phase 2 weight-loss data showed roughly 14.7% mean weight loss at 36 weeks at the highest dose, comparable to injectable semaglutide.

Phase 3 ATTAIN program (obesity) and ACHIEVE program (type 2 diabetes) have read out across 2025–2026; multiple late-Phase 3 readouts positive. FDA filing anticipated in 2026.

Strategic significance: a pill with injection-level efficacy and no food-timing requirement would change the cost, distribution, and adherence calculus of the entire class.

MariTide

MariTide (Maridebart Cafraglutide) — Monthly Injectable (Amgen)

Mechanism: GLP-1 agonist fused to a GIP-receptor antagonist antibody — a novel mechanism that may produce longer-duration weight loss with weight maintenance after discontinuation.

Phase 2 data showed up to ~20% mean weight loss at one year with monthly or less-frequent dosing. Trial signals suggested weight loss continuing for weeks after the last dose, consistent with the long half-life.

Phase 3 MARITIME program: ongoing in 2025–2026. The interest is whether monthly dosing meaningfully improves adherence and whether the post-discontinuation weight regain profile differs from weekly GLP-1s.

CagriSema

CagriSema — Amylin + Semaglutide (Novo Nordisk)

Mechanism: cagrilintide (long-acting amylin analog) co-formulated with semaglutide. Amylin is the other major satiety hormone and works through complementary pathways.

REDEFINE-1 Phase 3 results (announced late 2024) showed approximately 22.7% mean weight loss at 68 weeks — below pre-trial expectations of ~25% and a notable miss against the implicit benchmark, though still numerically the largest documented for a semaglutide-based combination.

Subsequent REDEFINE program readouts will determine FDA filing strategy. Novo's competitive positioning vs. tirzepatide and retatrutide remains the strategic question.

What else

Other Programs Worth Knowing

• ·Survodutide (Boehringer/Zealand): GLP-1/glucagon dual; Phase 3 MASH and obesity programs.
• ·Pemvidutide (Altimmune): GLP-1/glucagon dual; Phase 3 MASH program.
• ·Ecnoglutide and other Chinese-developed GLP-1s: increasing Phase 2/3 activity from Hansoh, Innovent, and others.
• ·Combination strategies — bimagrumab (muscle-sparing antibody) with semaglutide and others — are entering trials specifically to address the lean-mass loss problem documented with monotherapy GLP-1s.

Practical

What This Means for Today's Patients

Patients starting therapy today should not delay treatment waiting for pipeline drugs. Tirzepatide produces 18–22% mean weight loss with established safety. Better drugs may arrive in 2026–2028; patients delaying treatment in the interim accumulate the cardiovascular and metabolic costs of untreated obesity.

Class-switch conversations will become more common as new agents arrive. Patients comfortable on semaglutide today may be candidates for switching to retatrutide, orforglipron, or others as the data and FDA labeling allow.